Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Rigel (Nasdaq: RIGL) announced that Raul Rodriguez, president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:00 PM PT (6:00 PM ET).
The presentation will be available via live webcast and archived recording through Rigel's Investor Relations site at www.rigel.com; investors are advised to connect to the website before the start to allow any required software downloads.
Positive
- None.
Negative
- None.
News Market Reaction – RIGL
In the Jan 7 session, RIGL gained 8.66%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.4% during that session. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference appearance | Neutral | +2.8% | Piper Sandler healthcare conference presentation with webcast access details. |
| Nov 17 | Clinical data update | Positive | +1.4% | Publication of final 5-year REZLIDHIA Phase 2 data in R/R mIDH1 AML. |
| Nov 12 | Conference appearance | Neutral | +5.2% | Jefferies Global Healthcare Conference presentation and webcast details. |
| Nov 04 | Earnings update | Positive | -7.4% | Strong Q3 2025 revenues, net income, and raised full‑year guidance. |
| Nov 03 | Scientific meeting data | Positive | -2.9% | Multiple ASH presentations with updated R289 and REZLIDHIA clinical data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference and data announcements have often coincided with modest positive moves, while strong earnings once saw a negative reaction.
Over the last few months, Rigel has combined solid financial execution with increased visibility. Q3 2025 results reported revenue of $69.5M and net income of $27.9M, followed by raised 2025 revenue guidance. The stock, however, fell 7.41% after that earnings release. In contrast, conference and presentation headlines on Nov 3, Nov 12, and Nov 26, 2025 produced mixed but generally smaller moves, suggesting investors treat such appearances as incremental visibility events rather than major catalysts.
Key Terms
hematologic disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302654554.html
SOURCE Rigel Pharmaceuticals, Inc.